pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
19h
Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer
endpoints
19h
As part of sales reorganization, Novo will cut 215 employees at US HQ
biospace
20h
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
biospace
20h
Merck-Kelun ADC scores survival win in Phase 3 stomach cancer trial
biospace
20h
Researchers explore possibility of a CTE blood test
stat
21h
Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
biopharma dive
21h
Celldex culls eczema study after Phase 2 failure
endpoints
1d
Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
fiercebiotech
1d
Bausch + Lomb and Celldex rocked by respective phase 2 flops
fiercebiotech
1d
Study raises doubts about combining vaccine, monoclonal antibody to protect against malaria
stat
1d
Novartis projects slowed growth, pins hopes on billions in pipeline potential
biospace
1d
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
biopharma dive
2d
Vaccine biotech Evaxion halts infectious disease, autoimmune work to focus on oncology
fiercebiotech
2d
AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
biospace
2d
AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets
endpoints
2d
Teva loses R&D head Eric Hughes amid push to grow innovative medicines business
fiercebiotech
2d
Ramping up: 3 biotechs growing their workforce after series C raises
biospace
2d
Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustment
fiercebiotech
2d
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
2d
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
biopharma dive
2d
AbbVie busts a move with Disco in $2.5B dance aimed at bispecific discovery
fiercebiotech
2d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
3d
5 acquisitions that forced Big Pharmas to co-parent
biospace
3d
Cognito phase 3 flops in light-and-sound Alzheimer's trial, but sees ‘signal’ for HOPE
fiercebiotech
3d
FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss
fiercebiotech
3d
Novo revamps its direct-to-consumer platform; Roche drug Gazyva approved again
endpoints
3d
Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
biospace
3d
Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
biospace
3d
Marrow sets out to challenge genetic medicines for severe blood diseases
biopharma dive
4d
Kyntra axes mid-stage ADC, adding to years of stumbles
fiercebiotech
← prev
page 1 of 27
next →